Pregled bibliografske jedinice broj: 1253204
SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC) // Acta clinica Croatica, 61 (2022), Supplement 3; 81-85 doi:10.20471/acc.2022.61.s3.12 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1253204 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE
SENSITIVE PROSTATE CANCER (MHSPC)
Autori
Omrčen, Tomislav
Izvornik
Acta clinica Croatica (0353-9466) 61
(2022), Supplement 3;
81-85
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
hormone-sensitive prostate cancer ; systemic therapy ; novel hormonal therapy ; taxanes ; triple therapy
Sažetak
For many years, androgen deprivation therapy (ADT) as monotherapy has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies have been published within the last decade demonstrating a significant survival advantage resulting from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted therapy (ARTA) compared to ADT monotherapy. Recently published data of the PEACE-1 and ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients with mHSPC.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
